公开(公告)号：US20230293657A1

公开(公告)日：2023-09-21

申请号：US18001525

申请日：2021-06-17

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Maria Paula CARRANZA SANDMEIER ,  Rainer FOLLADOR ,  Veronica Gambillara FONCK ,  Stefan Jochen KEMMLER ,  Patricia Martin KILLIAS ,  Michael Thomas KOWARIK ,  Gerd Martin LIPOWSKY ,  Gerald Johann POSCH ,  Fabio SERVENTI ,  Dominique Nicolas SIRENA

IPC: A61K39/108 ,  C07K14/26 ,  A61P31/04 ,  C12N9/10

CPC classification number: A61K39/0266 ,  C07K14/26 ,  A61P31/04 ,  C12N9/1081 ,  C12Y204/99019 ,  A61K2039/6068

Abstract: The present invention relates to the field of immunogenic compositions and vaccines, their manufacture, host cells which can be used in their manufacture and the use of such immunogenic compositions and vaccines in medicine. More particularly, it relates to Klebsiella pneumoniae O-antigens, conjugates comprising a K. pneumoniae O-antigen, host cells suitable for their production and immunogenic compositions or vaccines containing at least one Klebsiella pneumoniae O-antigen.

公开(公告)号：US20230266317A1

公开(公告)日：2023-08-24

申请号：US17641315

申请日：2020-09-09

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Michael CHAPLET ,  Nathalie NORAIS ,  Simona RONDINI ,  Silvia ROSSI PACCANI

IPC: G01N33/569 ,  C07K16/12

CPC classification number: G01N33/56911 ,  C07K16/1203 ,  G01N2333/212 ,  C07K2317/33

Abstract: The present invention relates to in vitro assays, more particularly ELISA assays. Said ELISA assays comprise antibodies capable of binding Ubiquitous surface protein A2 (UspA2) from Moraxella catarrhalis. The present invention relates to assays for assessing the binding of antibodies to UspA2 and the relative potency of vaccine test samples comprising UspA2. In particular, the invention relates to in vitro relative potency assays used in the release of vaccine that comprises UspA2 to the public.

公开(公告)号：US20230263877A1

公开(公告)日：2023-08-24

申请号：US17769130

申请日：2020-10-15

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Francesco Citiulo ,  Laura Bartle Martin ,  Allan James Saul

IPC: A61K39/112 ,  A61P31/04

CPC classification number: A61K39/0283 ,  A61P31/04 ,  A61K2039/55572

Abstract: A Shigella flexneri O-antigen of a first serotype or subserotype are provided for use in raising an immune response against one or more Shigella flexneri O-antigen of a different serotype or subserotype, together with associated binding moieties, pharmaceutical compositions, kits, uses or methods.

公开(公告)号：US11717529B2

公开(公告)日：2023-08-08

申请号：US18065089

申请日：2022-12-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall ,  Katrin Ramsauer ,  Gillis Otten ,  Christian Walter Mandl

IPC: A61K39/00 ,  A61K39/12 ,  A61K31/7088

CPC classification number: A61K31/7088 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2770/36143

Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.

公开(公告)号：US20230242593A1

公开(公告)日：2023-08-03

申请号：US17946383

申请日：2022-09-16

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA ,  THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： KIMBERLY DOWD ,  BARNEY S. GRAHAM ,  SUNG-YOUL KO ,  WING-PUI KONG ,  JOHN MASCOLA ,  THEODORE PIERSON ,  MAYURI SHARMA ,  DONG YU

IPC: C07K14/005 ,  A61K39/12 ,  C12N7/00

CPC classification number: C07K14/005 ,  A61K39/12 ,  C12N7/00 ,  A61K2039/53

Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.

公开(公告)号：US20230226175A1

公开(公告)日：2023-07-20

申请号：US18001498

申请日：2021-06-17

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Stefan Jochen KEMMLER ,  Christian LIZAK ,  Gerald Johann POSCH ,  Julien Laurent QUEBATTE

IPC: A61K39/385 ,  A61K39/108 ,  C12N9/10

CPC classification number: A61K39/385 ,  A61K39/0266 ,  C12N9/1077 ,  C12Y204/02036

Abstract: The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising the modified proteins, their manufacture and the use of such compositions in medicine. More particularly, it relates to a modified EPA (Exotoxin A of Pseudomonas aeruginosa) protein. The modified EPA can be used as a carrier protein for other antigens, particularly saccharide antigens or other antigens lacking T cell epitopes.

公开(公告)号：US20230116636A1

公开(公告)日：2023-04-13

申请号：US18080101

申请日：2022-12-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew GEALL ,  Katrin RAMSAUER ,  Gillis OTTEN ,  Christian Walter MANDL

IPC: A61K31/7088 ,  A61K39/00 ,  A61K39/12

Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.

公开(公告)号：US20230114607A1

公开(公告)日：2023-04-13

申请号：US18065089

申请日：2022-12-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew GEALL ,  Katrin RAMSAUER ,  Gillis OTTEN ,  Christian Walter MANDL

IPC: A61K31/7088 ,  A61K39/00 ,  A61K39/12

Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.

公开(公告)号：US11591364B2

公开(公告)日：2023-02-28

申请号：US16768402

申请日：2018-11-30

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Ahmad Taimour Baig ,  Felicie Georgette Colette Denet ,  Juan Jose Diaz Garcia ,  Chad Austin Farrenburg ,  Lora Lea Lawrence ,  Kent Raymond Myers ,  Jeri Kay Sandvick ,  Jeb Yeatts Vandenburg

IPC: A61K39/39 ,  C07J63/00 ,  A61K39/12 ,  A61K39/25 ,  C12N7/00 ,  A61K39/00

Abstract: Saponin extracts containing at least 93% QS-21 main peak and 0.25-3% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects.

公开(公告)号：US11571472B2

公开(公告)日：2023-02-07

申请号：US15318490

申请日：2015-06-12

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Ann-Muriel Steff ,  Jean-Francois Toussaint ,  Alessandra Vitelli

IPC: A61K39/155 ,  A61K39/235 ,  A61K39/12 ,  A61K39/00

Abstract: Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.